Plain-English translation of NCT07046455 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are testing a new imaging scan called 89Zr-DFO-hSR7 PET to see if it can better detect and monitor advanced triple-negative breast cancer in patients receiving sacituzumab govitecan. This imaging scan works by targeting a specific protein on cancer cells, which may help doctors see tumors more clearly and track whether the medication is working.
Triple-negative breast cancer is a particularly aggressive type that is difficult to treat. Current imaging methods have limitations in detecting how well treatments are working. This new imaging scan may help doctors monitor treatment response more accurately and detect when cancer is becoming resistant to therapy earlier.
You likely qualify if…
You likely don't qualify if…
You will receive the medication sacituzumab govitecan as part of your cancer treatment plan. You will have special imaging scans (PET/CT) done before you start treatment and again after treatment to see how the cancer is responding. You will also need blood tests to monitor your health during the study, and researchers will follow up with you to track how you are doing and whether the cancer is responding to therapy.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
China